scholarly journals Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses

2020 ◽  
Vol 6 (10) ◽  
pp. eaaz4204 ◽  
Author(s):  
Yu Chao ◽  
Chao Liang ◽  
Huiquan Tao ◽  
Yaran Du ◽  
Di Wu ◽  
...  
Keyword(s):  
Cell Death ◽  
Immune Responses ◽  
Cancer Recurrence ◽  
Immune Checkpoint Blockade ◽  
Systemic Toxicity ◽  
Immunogenic Cell Death ◽  
In Situ Gelation ◽  
Immune Adjuvants ◽  
Immune Adjuvant

Currently, there is a huge demand to develop chemoimmunotherapy with reduced systemic toxicity and potent efficacy to combat late-stage cancers with spreading metastases. Here, we report several “cocktail” therapeutic formulations by mixing immunogenic cell death (ICD)–inducing chemotherapeutics and immune adjuvants together with alginate (ALG) for localized chemoimmunotherapy. Immune checkpoint blockade (ICB) antibody may be either included into this cocktail for local injection or used via conventional intravenous injection. After injection of such cocktail into a solid tumor, in-situ gelation of ALG would lead to local retention and sustained release of therapeutics to reduce systemic toxicity. The chemotherapy-induced ICD with the help of immune adjuvant would trigger tumor-specific immune responses, which are further amplified by ICB to elicit potent systemic antitumor immune responses in destructing local tumors, eliminating metastases and inhibiting cancer recurrence. Our strategy of combining clinically used agents for tumor-localized cocktail chemoimmunotherapy possesses great potential for clinical translation.

Combining PD-L1 Inhibitors with Immunogenic Cell Death Triggered by Chemo-Photothermal therapy via a Thermosensitive Liposome System to Stimulate Tumor-specific Immunological Response

Nanoscale ◽  
2021 ◽  
Author(s):  
Jie Yu ◽  
Xidong He ◽  
Zigui Wang ◽  
Yu Peng Wang ◽  
Sha Liu ◽  
...  
Keyword(s):  
Cell Death ◽  
Immune Responses ◽  
Photothermal Therapy ◽  
Immunological Response ◽  
Immune Checkpoint Blockade ◽  
Immunogenic Cell Death ◽  
Adaptive Immune Responses ◽  
Adaptive Immune ◽  
Thermosensitive Liposome ◽  
Liposome System

Immune checkpoint blockade (ICB) therapy in combination with immunogenic death (ICD) triggered by photothermal therapy (PTT) and oxaliplatin (OXA) treatment was expected to elicit both innate and adaptive immune responses...

Tumor Microenvironment-Triggered In-Situ Cancer Vaccines with Dual Immunogenic Cell Death Inductions for Elevated Antitumor and Antimetastatic Therapy

Nanoscale ◽  
2021 ◽  
Author(s):  
Jun Lin ◽  
Binbin Ding ◽  
Pan Zheng ◽  
Dong Li ◽  
Meifang Wang ◽  
...  
Keyword(s):  
Cell Death ◽  
Tumor Microenvironment ◽  
Immune Responses ◽  
Cancer Immunotherapy ◽  
Cancer Vaccines ◽  
High Specificity ◽  
The Body ◽  
Immunogenic Cell Death ◽  
Specific Antigens

Cancer vaccine is to make tumor-specific antigens into vaccines, which then are injected back into the body to activate immune responses for cancer immunotherapy. Despite the high specificity and therapeutic...

scholarly journals Biomarkers of Radiotherapy-Induced Immunogenic Cell Death

Cells ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 930
Author(s):  
Rianne D. W. Vaes ◽  
Lizza E. L. Hendriks ◽  
Marc Vooijs ◽  
Dirk De Ruysscher
Keyword(s):  
Cell Death ◽  
Immune Responses ◽  
Tumor Cells ◽  
Immunogenic Cell Death ◽  
Type I ◽  
Future Studies ◽  
Regulated Cell Death ◽  
Molecular Patterns ◽  
Damage Associated Molecular Patterns ◽  
Potential Biomarkers

Radiation therapy (RT) can induce an immunogenic variant of regulated cell death that can initiate clinically relevant tumor-targeting immune responses. Immunogenic cell death (ICD) is accompanied by the exposure and release of damage-associated molecular patterns (DAMPs), chemokine release, and stimulation of type I interferon (IFN-I) responses. In recent years, intensive research has unraveled major mechanistic aspects of RT-induced ICD and has resulted in the identification of immunogenic factors that are released by irradiated tumor cells. However, so far, only a limited number of studies have searched for potential biomarkers that can be used to predict if irradiated tumor cells undergo ICD that can elicit an effective immunogenic anti-tumor response. In this article, we summarize the available literature on potential biomarkers of RT-induced ICD that have been evaluated in cancer patients. Additionally, we discuss the clinical relevance of these findings and important aspects that should be considered in future studies.

scholarly journals 456 Bortezomib induces immunogenic cell death in melanoma and enhances immune responses in vivo

2019 ◽  
Vol 139 (9) ◽  
pp. S293
Author(s):  
S.M. Daignault ◽  
R.J. Ju ◽  
L. Spoerri ◽  
S.J. Stehbens ◽  
R. Dolcetti ◽  
...  
Keyword(s):  
Cell Death ◽  
Immune Responses ◽  
Immunogenic Cell Death

An aminophosphonate ester ligand-containing platinum(ii) complex induces potent immunogenic cell death in vitro and elicits effective anti-tumour immune responses in vivo

2019 ◽  
Vol 55 (87) ◽  
pp. 13066-13069 ◽  
Author(s):  
Ke-Bin Huang ◽  
Feng-Yang Wang ◽  
Hai-Wen Feng ◽  
Hejiang Luo ◽  
Yan Long ◽  
...  
Keyword(s):  
Cell Death ◽  
Immune Responses ◽  
Immunogenic Cell Death

A platinum(ii)-aminophosphonate complex (Pt1) induces potent anti-tumour immunogenic cell death (ICD) in vitro and in vivo.

Sign in / Sign up

Export Citation Format

Share Document